Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Bionano Genomics Earnings Call: Key Takeaways

BioNANO delivered 12% revenue growth driven by record flow cell sales and improved gross margins, while navigating supply constraints and targeting EBITDA neutrality by 2027.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthAmericas grew 35% to $3.8M; EMEA grew 14% to $4.1M.
Mgmt ConfidenceConfident in 2027 EBITDA neutrality through controlled expenses and top-line growth.
Demand VisibilityStrong customer demand noted; currently limited by silicon wafer supply constraints.
Order BookBacklog exists due to supply constraints; expect to clear by year-end.
Margin TrendsAdjusted gross margin improved to 48% from 46% year-over-year.
Op. LeverageOperating expenses decreased 12% to $10.5M; adjusted OpEx down 9%.
Vol vs PriceVolume-led growth with record 9,870 flow cells sold, up 18%.
Segment GrowthConsumables up 24%; Instruments/Services up 24%; Software down 31%.
New ClientsUniversity of Rochester and Memorial Sloan Kettering launched OGM-based testing.
Capex & DebtEnded quarter with $8.7M in cash and equivalents.
RegulatoryProposed Moldex LCD for Medicare coverage in 31 US states.
CommentaryShifted from aggressive installed base growth to profitable routine-use utilization.

Growth

Revenue grew 12% to $8.3M; consumables up 24% to $4.7M; flow cells up 18%.

Outlook

Reiterated 2026 revenue of $31M-$33M; targeting EBITDA neutrality by end of 2027.

Risks

Management used vague language regarding specific 2027 revenue drivers and Sloan Kettering implementation details.

Source

The company's earnings call, NASDAQ: BNGO, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Bionano Genomics, Inc.: key numbers

Share price
$0.9400Close, Nov 16
Market cap
$13.1M
Shares outstanding
13.99MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Laboratory Analytical InstrumentsSIC 3826

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Bionano Genomics, Inc.

All →
4:11 PM ET 10-Q
Financial Results ▶ Call

Bionano Genomics Q3 2026 Results: Net Loss of $6.45M, Loss Narrows

Bionano Genomics reported total revenue of $8.28 million for the third quarter of 2026, a 12% increase year-over-year, while narrowing its quarterly net loss to $6.45 million compared to $8.50 million in 2025. The company's cash position remains tight, with total cash, cash equivalents, and investments decreasing significantly from $19.27 million at the end of 2025 to $8.17 million as of September 30, 2026.

Key figure
Net loss $6.45M
4:04 PM ET 8-K
Financial Results

Bionano Genomics Financial Results

Bionano Genomics reported Q3 2026 revenue of $8.3 million, a 12% increase year-over-year, driven by a 24% rise in consumables revenue. The company reiterated its full-year 2026 revenue guidance of $31 million to $33 million and highlighted progress in the clinical adoption of its optical genome mapping (OGM) technology.

Term
Q3 2026

“Our third quarter results reflect the momentum building across our business and the broader genomics community, further accelerating the adoption of optical genome mapping (OGM) in clinical and commercial settings.”

Al Luderer, Ph.D., chairman and interim chief executive officer

“Coverage and regulatory progress this quarter helped build a clearer reimbursement pathway for OGM-based testing, which we expect to support broader clinical adoption over time.”

Al Luderer, Ph.D., chairman and interim chief executive officer
8:31 AM ET 8-K
Investor Presentation

Bionano Genomics Investor Presentation

Bionano Genomics Chairman and Interim CEO Al Luderer is presenting at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The company filed its conference presentation deck as an exhibit, which includes updates on its business strategy, optical genome mapping (OGM) adoption, and cost-saving initiatives. The presentation also addresses the company's focus on extending its cash runway and reaching a pathway to profitability.

Counterparty
H.C. Wainwright

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.